Prestige Consumer Healthcare: Better Valuation, But Too Much Uncertainty To Buy

Prestige ended Fiscal Year 2026 with a big earnings miss and is expected to have a slow start to FY27. While acquisitions should lift the top line, they also add more debt to an already leveraged balance sheet. The outlook is pressured by weak near-term performance and increased leverage risk.

Analysis

Prestige ended Fiscal Year 2026 with a big earnings miss and is expected to have a slow start to FY27. While acquisitions should lift the top line, they also add more debt to an already leveraged balance sheet. The outlook is pressured by weak near-term performance and increased leverage risk.